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Antibodies, such as anti-Rh18 (Hr/HrS), that react with the common
products of RHCE can cause HDN as well as severe hemolytic
transfusion reactions. Individuals with anti-Rh18 antibodies can
have different RHCE genetic backgrounds; therefore, sera and RBCs
from these individuals may cross-react. In these situations,
genotyping may be the best method to determine compatibility. We
report a 26-year-old pregnant Puerto Rican woman who presented
at 31 weeks’ gestation with anti-E and anti-Rh18 in her serum. No
potential donors were identified among family members or within
the American Rare Donor Program; therefore, a unit of the patient’s
RBCs was collected one week before her planned caesarian
section. To improve our ability to supply blood for this patient in
the future,molecular testing was performed. The patient was found
to be homozygous for an RH haplotype in which a variant
RHD*DAR, is linked to a variant RHCE*ceAR. The DAR-ceAR
haplotype has been described in Dutch-African populations, but
this is the first report of an individual self-identified of Hispanic
ethnicity. This case report demonstrates the clinical importance of
molecular testing of patients with rare Rh phenotypes.
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Anti-Rh18 (anti-Hr, anti-HrS) reacts with a high-
frequency antigen on the RhCE protein and was first
reported in 1960 in a pregnant South African woman
with the surname Shabalala.1 Adsorption studies identi-
fied two antibodies. One reacted with all common Rh
phenotypes and was called anti-Hr because of its
similarity with antibodies made by individuals with a
phenotype produced by an Rh deletion. The other had
anti-e-like specificity and was called anti-Shabalala 
(anti-Rh19, anti-hrS).
Anti-Rh18 has been implicated in HDN and
hemolytic transfusion reactions.1–3 Serologic identifi-
cation of these variant e phenotypes is difficult
because of the paucity of serum and lack of standard-
ization of reagents.4 In addition, sera and RBCs from
individuals with anti-Rh18 are not all compatible with
each other, as several different RHce genes may be
associated with a single variant e serologic phenotype.3
Although a great deal has been learned in the last
decade concerning the molecular basis of variant Rh
phenotypes (as summarized by Reid and Lomas-
Francis5), it is not yet commonplace to request blood
group antigen molecular testing on a patient,or to base
transfusion recommendations on the findings.6 This
report describes the serologic and molecular
management of a pregnant woman with anti-Rh18 and
highlights the value of molecular testing in patient care.
Case Report
A 26-year-old, group O, D+, pregnant Puerto Rican
woman (gravida-6, para-2, with two therapeutic and
one spontaneous abortion) presented at 31 weeks’
gestation with anti-E and -Rh18 in her serum. She had
no history of prior transfusions or children with HDN.
Because of the risk of HDN with the current
pregnancy, a search was initiated for potential blood
donors. With no family members available for donation
and no compatible donors registered in the American
Rare Donor Program (ARDP), a unit of the patient’s
RBCs was collected one week before her planned
caesarian section. For collection, she was brought to
the labor and delivery floor and attached to a fetal
heart monitor. She tolerated the donation well and
there was no evidence of fetal distress. At birth, the
baby’s RBCs were positive by the DAT but there was no
clinical evidence of hemolysis.
Materials and Methods
Serologic testing
Antibody detection was initially performed using a
column agglutination test (Ortho-Clinical Diagnostics,
Raritan, NJ) followed by additional tube testing with
either PEG or LISS enhancement (ImmucorGamma,
Norcross, GA). Common antigen typings were
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performed with commercially available cells and
antisera (ImmucorGamma; Ortho-Clinical Diagnostics).
Anti-hrS and hrS– RBCs were obtained through SCARF.
RBCs used for adsorption were treated with in-
house prepared ZZAP made with DTT and papain;
eluates were prepared using an acid elution method
from RBCs used in the first pass of adsorption (Elu-kit
II, ImmucorGamma). Indirect antiglobulin testing of
adsorbed plasma and eluates was performed using PEG
(Gamma PeG, ImmucorGamma) and murine IgG-
specific antihuman reagent (Anti-IgG, Immucor-
Gamma).
Titrations were performed using doubling dilutions
of plasma in 0.9% saline. DATs were performed using
murine polyspecific, IgG, C3b, and C3d component
specific antihuman globulin reagents (Anti-IgG, Anti-
C3bC3d, and AntiHuman Globulin, ImmucorGamma).
RBCs positive by the DAT were prepared for
phenotyping using an EDTA glycine-acid kit (EGA,
ImmucorGamma).
Molecular testing
Genomic DNA was isolated from the patient’s
WBCs through the use of a DNA extraction kit
(QIAamp Blood Mini Kit,QIAGEN,Hilden,Germany). A
previously published method employing multiplex
PCR was performed to test for the presence of RHD
exons 4 and 7, the inactivating pseudogene, and for C
and c genotyping.7 RHD zygosity was determined by
PCR detection of the hybrid Rhesus box, which is a
marker for the RHD deletion, and with a PCR-RFLP
method.8,9 PCRs were performed for RHD exon 10 and
RHCE and RHD intron 4 (designed in-house). PCR
products were separated on 2% agarose gels and
visualized with ethidium bromide staining.
RNA was isolated from the patient’s RBCs with a
specialized reagent (Trizol, Invitrogen, Carlsbad, CA)
and cDNA was synthesized with a kit (First Strand
cDNA Synthesis kit, Invitrogen,). The cDNA was
amplified with primers flanking the coding regions of
RHD and RHCE. PCR products were ligated into pCR
2.1-TOPO TA vector and transformed into chemically
competent E. coli cells (TOPO TA cloning kit,
Invitrogen). Positive clones were determined by color
selection with X-Gal. Plasmids were isolated with the
use of a kit (QIAprep Spin Mini kit, Qiagen) and
analyzed with restriction enzymes. Six plasmids
representing different Rh transcripts were sequenced
(Children’s Hospital of Philadelphia). Sequences were
aligned and compared using Clustal X.
Results
Serologic investigation
The patient’s RBCs initially typed as group O, D+
and her plasma reacted with all RBCs tested using
column agglutination testing and tube testing with PEG
(3-4+) and using tube testing with LISS (1-3+). The DAT
and autocontrol were negative. Staff at the American
Red Cross (ARC) reference laboratories in Dedham,
Massachusetts, and in Philadelphia, Pennsylvania,
phenotyped the patient’s RBCs as: group O, D, C–, E–,
c+, e+. They also identified anti-E, -Hr, and -hrS. Her
serum did not react with –D– RBCs.
To confirm the serologic findings, aliquots of the
patient’s plasma were adsorbed onto rr and R2R2 RBCs.
Adsorbed plasma and the eluates were tested against
E+e–, E–e+, E–e+hrS– RBCs. After adsorption onto rr
RBCs, the patient’s plasma reacted only with E+e–
RBCs, confirming the presence of anti-E. The eluate
prepared from rr RBCs used for adsorption reacted
with E+e– RBCs confirming the presence of anti-Hr.
After adsorption onto R2R2 RBCs, the patient’s plasma
reacted with only E–e+ RBCs and not with E–e+,hrS–
RBCs, confirming the presence of anti-hrS.
Titration studies were performed on the patient’s
serum in the third trimester of pregnancy. The titer
against E+,e+,hrS– RBCs was 4 with a score of 16. The
titer against E–,e+ RBCs was 0 with a score of 8. At
birth, the infant’s RBCs typed as E-, hrS+ and the DAT
was positive with anti-IgG. The Hct was 40.2 percent
with a total bilirubin of 2.1 g/dL.
Molecular investigation
Testing on genomic DNA indicated the presence of
RHD exons 4, 7, and 10 and intron 4 and was negative
for the inactivating RHD pseudogene found in the
Black population. The absence of the hybrid Rhesus
box indicated a RHD homozygote.8 The PstI PCR-RFLP
assay was incon-clusive as has been reported
previously for some ethnic groups.10
The cDNA sequence analysis identified two
different transcripts, a variant RHce, ceAR, and a variant
RHD, DAR (Fig. 1). The ceAR allele is characterized by
polymorphisms 48G>C (W16C), 712A>G (M238V),
733C>G (L245V), 787A>G (R263G), 800T>A (M267K),
and 916A>G (I306V). This allele is associated with hrS–
and VS– phenotypes. The DAR allele is characterized
by changes 602C>G (T201R), 667T>G (F223V), and
1025T>C (I342T).11 The DAR allele, also termed weak
D type 4.2, is associated with a weak D phenotype and
the production of anti-D.
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Discussion
Anti-Rh18 is known to cause HDN. The antibody
was first discovered in the serum of a South African
woman whose newborn had severe jaundice requiring
exchange transfusion.1 Moores has since reported
seven additional cases of HDN related to anti-Rh18
requiring exchange transfusion.2
This report describes the use of serologic and
molecular methods in the management of a pregnant
woman with anti-Rh18. With the risk of HDN, a search
was initiated for an Rh:-18 unit. The uncommon nature
of this phenotype is evidenced by the lack of an
available compatible donor in the ARDP. Procurement
of overseas blood was deemed too risky regarding
infectious disease testing,and the decision was made to
collect an autologous unit from the patient one week
before her planned caesarian section. This report and
others demonstrate that blood can be donated safely
even late in pregnancy.12
Anti-Rh18 has caused fatal hemolytic transfusion
reactions but identification of compatible donors is
hampered by the lack of reagents and poor
standardization of serum used for identification of rare
RHCE phenotypes.3,4 The uncertain nature of reactivity
between these samples is emphasized by a report from
2002.3 Two patients identified by serologic testing to
have anti-Rh18 did not have compatible serum and
RBCs. In these patients with variant Rh phenotypes,
compatible donors are best located through RH
genotyping.
Noizat-Pirenne identified three RHCE alleles, ceAR,
ceEK, and ceMO, in Afro-Caribbean patients associated
with hrS– phenotype that can lead to formation of anti-
Rh18.3 The patient described here was homozygous
for variant RHCE, ceAR, linked to variant RHD, DAR
which explained production of anti-Rh18 and -hrS as
well as her weak D phenotype. In a group of 326 Black
South African blood donors, DAR was present in 4.9
percent of these individuals,ceAR in approximately 6.1
percent and DAR/ceAR in 4.3 percent.11 This patient
stated her ethnic back-
ground as Hispanic,
demonstrating that groups
other than those that
identify themselves as
Black have variant Rh
haplotypes.
Unfortunately, since
hrS– phenotypes can have
varying molecular
backgrounds, it is extremely difficult to find compatible
units for transfusion of these patients. Also, as this case
illustrates, many of these variant RHce are inherited
with variant RHD genes that are associated with the
formation of anti-D. As more units are RH molecularly
characterized throughout the country, it will become
easier to find compatible blood for future transfusion
support. In addition, the serum from this patient is
valuable for large-scale donor screening and will be
more informative because of the well-characterized RH
genotype. This will contribute to better understanding
of the reactivity patterns among variants.
There is clearly a role for molecular testing in
transfusion medicine. This report shows the feasibility
of RH genotyping and its potential for improving
management of patients with uncommon phenotypes.
In the future, increased RH genotyping of blood donors
and recipients, as well as distribution of rare sera and
genotyped RBCs, will increase the availability of rare
blood and improve patient care.
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